Swine Vaccines Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Swine Vaccines Market size was valued at USD 1.6 billion in 2023 and is expected to exhibit growth at a CAGR of 5.3% from 2024 to 2032. The increasing prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and African Swine Fever (ASF) compels farmers to adopt vaccination programs to prevent devastating outbreaks. This surge in disease prevalence significantly drives the growth of the market.
Additionally, technological advancements in vaccine development, such as recombinant and DNA vaccines, enhance efficacy and safety, making them more appealing to swine producers and further fueling market growth. Furthermore, government initiatives and support for vaccination programs, coupled with improved veterinary services and distribution networks, facilitate market expansion. Additionally, heightened awareness about animal healthcare and welfare among farmers leads to greater vaccine adoption, reinforcing the market's upward trajectory.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Swine Vaccines Market size in 2023: | USD 1.6 Billion |
Forecast Period: | 2024 - 2032 |
Forecast Period 2023 - 2032 CAGR: | 5.3 |
2023 Value Projection: | USD 2.5 Billion |
Historical Data for: | 2021 - 2023 |
No of Pages: | 126 |
Tables, Charts & Figures: | 226 |
Segments Covered: | Product, Disease Type, End-user, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Swine vaccines are immunological products designed to protect pigs from infectious diseases, enhancing their health, productivity, and welfare. These animal vaccines stimulate the pig's immune system to develop immunity against specific pathogens, preventing outbreaks and reducing economic losses in the swine industry. Commonly targeted diseases include Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and swine influenza. Swine vaccines are essential tools in veterinary medicine, ensuring the sustainability and biosecurity of pig farming operations.
Based on product, the market is segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, subunit vaccines, toxoid vaccines, and other products. The inactivated vaccines segment accounted for USD 568.4 million in 2023 in the global market.
Based on disease type, the swine vaccines market is classified into porcine reproductive and respiratory syndrome (PRRS), porcine circovirus type 2 (PCV2), mycoplasma hyopneumoniae, classical swine fever (CSF), swine influenza, erysipelas, foot-and-mouth disease (FMD), African swine fever (ASF), porcine parvovirus, and other disease types. The porcine reproductive and respiratory syndrome (PRRS) segment held highest market share of 17.8% in 2023.
Based on end-user, the swine vaccines market is categorized into veterinary hospitals & clinics, swine farms, and research institutes. The veterinary hospitals & clinics segment dominated the global market and is poised to grow at 5% CAGR.
In 2023, the North American swine vaccines market was valued at USD 633.6 million and is expected to grow at a CAGR of 5.1% from 2024 to 2032.
The U.S. swine vaccines market, which accounted for USD 583.6 million in 2023, is projected to reach USD 893.6 million by 2032.
The swine vaccines market in China is set for remarkable growth in the coming years.
India is anticipated to grow at a considerable rate in the global swine vaccines market.
The market is characterized by a competitive landscape with several key players vying for market share. Companies such as Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco, and Merck & Co., Inc. are prominent in the market, leveraging extensive R&D investments to develop advanced vaccines. These companies focus on expanding their product portfolios to address a wide range of swine diseases, including Porcine Reproductive and Respiratory Syndrome (PRRS), Swine Influenza, and Foot-and-Mouth Disease (FMD).
Prominent players operating in the swine vaccines industry include:
Market, By Product
Market, By Disease Type
Market, By End-user
The above information is provided for the following regions and countries:
Ceva Sante Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck & Co., Inc., Phibro Animal Health Corporation, Vaxxinova, Virbac, and Zoetis Inc. among others.
In 2023, North America market was valued at USD 633.6 million and is expected to record a CAGR of 5.1% from 2024 to 2032, backed by the advanced veterinary infrastructure, supporting efficient vaccine distribution, administration, and monitoring, ensuring high vaccination coverage and effectiveness.
The inactivated vaccines segment accounted for USD 568.4 million in 2023, owing to their proven track record in preventing swine diseases, along with fewer side effects and adverse reactions, leading to widespread acceptance and trust among farmers and veterinarians.
The global swine vaccines industry was valued at USD 1.6 billion in 2023 and is anticipated to record a CAGR of 5.3% through 2032, backed by the increasing prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and African Swine Fever (ASF).